Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Regulators and industry stakeholders are reassessing whether body weight alone is a sufficient endpoint for obesity therapies. In a recent Boehringer Ingelheim discussion, Brian Hilberdink highlighted a shift toward metabolic health as a more meaningful indicator of clinical benefit. The
This article explains how batch surveillance system in pharma improves GMP oversight through real time batch monitoring GMP, stronger data integrity monitoring in pharma, and enhanced QA real time oversight pharma, enabling faster deviation detection and better inspection readiness across
In a feature published on June 16, 2026, BioSpace highlighted six real-world cases where drug development shifted from corporate strategy to deeply personal missions. The report shows how rare disease diagnoses within families of biotech leaders influenced company formation, clinical
Simcere Pharmaceutical Group has launched a research collaboration with Stanford Medicine to develop potential first-in-class therapies for idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease. Under this agreement announced on June 15, 2026, Simcere Pharmaceutical Group funds early
This article explains batch manufacturing record systems in the pharmaceutical industry, focusing on GMP documentation requirements, QA review processes, and pharmaceutical batch release process. It also highlights FDA GMP inspection findings, ALCOA+ data integrity, and CFR Part 11 compliance controls.
Sigma Healthcare pulled back from its early-stage attempt to acquire UK pharmacy giant Boots after concluding that the deal does not align with its strategic and capital priorities. The Australian pharmaceutical wholesaler shifted its focus back to its domestic market,
Johnson & Johnson unveiled phase 3 findings at the European Hematology Association Congress 2026 in Stockholm, highlighting the growing impact of bispecific antibodies in multiple myeloma treatment. Results from the MonumenTAL-3 phase 3 study showed that Talvey combined with Darzalex
Explore critical aspects of pharmaceutical batch control, focusing on documentation accuracy, electronic batch records, ALCOA plus principles, and GMP compliance. This article explains inspection risks, quality unit review, and batch release process for improved inspection readiness.